Роль антимюллерова гормона в женской репродукции

Антимюллеров гормон (АМГ) является одним из наиболее изучаемых в настоящее время биологически активных соединений. Его роль в процессах женской репродукции признается весьма значительной, но конкретные функции, механизмы их осуществления и регуляция образования самого АМГ остаются предметом исследований. В клинической практике определение уровней АМГ применимо в контексте предсказания ответа яичников на стимуляцию в программах вспомогательных репродуктивных технологий, а также для прогнозирования преждевременной овариальной недостаточности у женщин, подвергающихся терапии, потенциально токсичной для яичников. Одним из перспективных направлений является оценка уровня АМГ как способ прогнозирования и диагностики синдрома поликистозных яичников. Лекарственная терапия может оказать существенное влияние на синтез и секрецию АМГ. В качестве средства, прямо и опосредованно позитивно воздействующих на уровень АМГ выделяются аналоги гонадолиберина.

антимюллеров гормон, фолликулогенез, овуляция, овариальный резерв, контролируемая индукция овуляции, ожирение, синдром поликистозных яичников, преждевременная недостаточность яичников, эндометриоз, аналоги гонадолиберина

1. J. Visser JA, Durlinger ALL, Peters IJJ, van den Heuvel ER, Rose UM, Kramer P, et al. Increased Oocyte Degeneration and Follicular Atresia during the Estrous Cycle in Anti-Müllerian Hormone Null Mice. Endocrinology 2007; J48: 230J-8. doi:J0.J2J0/ en.2006-J265.

2. Nilsson E, Rogers N, Skinner MK. Actions of anti-Mullerian hormone on the ovarian transcriptome to inhibit primordial to primary follicle transition. Reproduction 2007; J34: 209-2J. doi:J0.J530/REP-07-0JJ9.

3. Fang Y, Lu X, Liu L, Lin X, Sun M, Fu J, et al. Vascular endothelial growth factor induces anti-Müllerian hormone receptor 2 overexpression in ovarian granulosa cells of in vitro fertilization/intracytoplasmicsperm injection patients. Mol. Med. Rep 20J6; J3: 5J57-62. doi:J0.3892/mmr.20J6.5J73.

4. Andersen CY, Schmidt KT, Kristensen SG, Rosendahl M, Byskov AG, Ernst E. Concentrations of AMH and inhibin-B in relation to follicular diameter in normal human small antral follicles. Hum. Reprod. 20J0; 25: J282- doi:J0.J093/humrep/deq0J9.

5. Jeppesen JV, Anderson RA, Kelsey TW, Christiansen SL, Kristensen SG, Jayaprakasan K, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection. Mol. Hum. Reprod. 20J3; J9:5J9-27. doi:J0. J093/molehr/gat024.

6. Grynberg M, Pierre A, Rey R, Leclerc A, Arouche N, Hesters L, et al. Differential Regulation of Ovarian Anti-Müllerian Hormone (AMH) by Estradiol through a- and ß-Estrogen Receptors. J. Clin. Endocrinol. M.etab 20J2; 97: E J649-57. doi:J0.J2J0/ jc.20JJ-3J33.

7. Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod. Biomed. Online 20J0; V20: B280-5. doi:J0.J0J6/j. rbmo.2009.JJ.0J0.

8. Lie Fong S, Laven JSE, Hakvoort-Cammel FGAJ, Schipper I, Visser JA, Themmen APN, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum. Reprod. 2009; 24: 982-90. doi:J0.J093/humrep/den487.

9. Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, et al. Impact of cancer therapies on ovarian reserve. Fertil. Steril. 20J2; 97: J34-J40.eJ. doi:J0.J0J6/j. fertnstert.20JJ.J0.040.

10. . Anderson RA, Rosendahl M, Kelsey TW, Cameron DA. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur. J. Cancer 20J3; 49: 3404-JJ. doi:J0.J0J6/j.ejca.20J3.07.0J4.

11. Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, et al. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil. Steril. 20J3; 99: 477-483.eJ. doi:J0.J0J6/j.fertn-stert.20J2.09.039.

12. Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, L0ssl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil. Steril. 20J0; 94: J56-66. doi:J0.J0J6/j.fertn-stert.2009.02.043.

13. Lawrenz B, Mahajan N, Fatemi HM. The effects of cancer therapy on women’s fertility: what do we know now? Futur. Oncol. 20J6; J2: J72J-9. doi:J0.22J7/fon-20J5-0004.

14. Brougham MFH, Crofton PM, Johnson EJ, Evans N, Anderson RA, Wallace WHB. Anti-Müllerian Hormone Is a Marker of Gonadotoxicity in Pre- and Postpubertal Girls Treated for Cancer: A Prospective Study. J. Clin. Endocrinol. Metab. 20J2; 97:2059-67. doi:J0.J2J0/jc.20JJ-3J80.

15. Hagen CP, Vestergaard S, Juul A, Skakkebcek NE, Andersson A-M, Main KM, et al. Low concentration of circulating antimüllerian hormone is not predictive of reduced fecundability in young healthy women: a prospective cohort study. Fertil. Steril. 20J2; 98: J602-J608.e2. doi:J0.J0J6/j. fertnstert.20J2.08.008.

16. Nelson SM, Yates RW, Fleming R. Serum an-ti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles implications for individualization of therapy. Hum. Reprod. 2007; 22:24J4-2J. doi:J0.J093/humrep/dem204.

17. Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive response in controlled ovarian hyperstimulation: a meta-analysis. Hum. Reprod. Update2011; 17: 46-54. doi:10.1093/humupd/dmq034.

18. Yates AP, Rustamov O, Roberts SA, Lim HYN, Pemberton PW, Smith A, et al. Anti-Mullerian hormone-tailored stimulation protocols improve outcomes whilst reducing adverse effects and costs of IVF. Hum. Reprod. 2011; 26:2353-62. doi:10.1093/ humrep/der182.

19. Anderson RA, Nelson SM, Wallace WHB. Measuring anti-Müllerian hormone for the assessment of ovarian reserve: When and for whom is it indicated? Maturitas 2012; 71: 28-33. doi:10.1016/j.maturitas.2011.11.008.

20. Broer SL, Dolleman M, van Disseldorp J, Broeze KA, Opmeer BC, Bossuyt PMM, et al. Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: an individual patient data meta-analysis. Fertil. Steril. 2013;100:420-429. e7. doi:10.1016/j.fertnstert.2013.04.024.

21. Freeman E, Gracia C, Sammel M, Lin H, Lim L, Strauss III J. Association of anti-mullerian hormone levels with obesity in late reproductive-age women. Fertil. Steril. 2007; 87: 101-6. doi:10.1016/j.fertnstert.2006.05.074.

22. MerhiZ, BuyukE, BergerDS, Zapantis A, Israel DD, Chua S, et al. Leptin suppresses anti-Mullerian hormone gene expression through the JAK2/STAT3 pathway in luteinized granulosa cells of women undergoing IVF. Hum. Reprod. 2013; 28: 1661-9. doi:10.1093/humrep/ det072.

23. Park HT, Cho GJ, Ahn KH, Shin JH, Kim YT, Hur JY, et al. Association of insulin resistance with anti-Mullerian hormone levels in women without polycystic ovary syndrome (PCOS). Clin. Endocrinol. (Oxf) 2010; 72: 26-31. doi:10.1111/j.1365-2265.2009.03614.x.

24. Lie Fong S, Schipper I, de Jong FH, Themmen APN, Visser JA, Laven JSE. Serum anti-Müllerian hormone and inhibin B concentrations are not useful predictors of ovarian response during ovulation induction treatment with recombinant follicle-stimulating hormone in women with polycystic ovary syndrome. Fertil. Steril. 2011; 96: 459-63. doi:10.1016/j. fertnstert.2011.05.084.

25. Pellatt L, Hanna L, Brincat M, Galea R, Brain H, Whitehead S, et al. Granulosa Cell Production of Anti-Müllerian Hormone Is Increased in Polycystic Ovaries. J. Clin. Endocrinol. Metab. 2007; 92: 240-5. doi:10.1210/ jc.2006-1582.

26. Catteau-Jonard S, Jamin SP, Leclerc A, Gonzales J, Dewailly D, di Clemente N. Anti-Mullerian Hormone, Its Receptor, FSH Receptor, and Androgen Receptor Genes Are Overexpressed by Granulosa Cells from Stimulated Follicles in Women with Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 2008; 93:4456-61. doi:10.1210/jc.2008-1231.

27. Pierre A, Peigne M, Grynberg M, Arouche N, Taieb J, Hesters L, et al. Loss of LH-induced down-regulation of anti-Müllerian hormone receptor expression may contribute to anovulation in women with polycystic ovary syndrome. Hum. Reprod. 2013; 28: 762-9. doi:10.1093/humrep/des460.

28. Thathapudi S, Kodati V, Erukkambattu J, Addepally U, Qurratulain H. Association of Luteinizing Hormone Chorionic Gonadotropin Receptor Gene Polymorphism (rs2293275) with Polycystic Ovarian Syndrome. Genet. Test Mol. Biomarkers 2015; 19: 128-32. doi:10.1089/gtmb.2014.0249.

29. Lamminen T, Jiang M, Manna PR, Pakarinen P, Simonsen H, Herrera RJ, et al. Functional study of a recombinant form of human LH-beta-subunit variant carrying the Gly(102) Ser mutation found in Asian populations. Mol. Hum. Reprod. 2002; 8: 887-92.

30. Dewailly D, Gronier H, Poncelet E, Robin G, Leroy M, Pigny P, et al. Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum. Reprod. 2011; 26: 3123-9. doi:10.1093/humrep/der297.

31. Robin G, Gallo C, Catteau-Jonard S, Lefebvre-Maunoury C, Pigny P, Duhamel A, et al. Polycystic Ovary-Like Abnormalities (PCO-L) in Women with Functional Hypothalamic Amenorrhea. J. Clin. Endocrinol. Metab. 2012; 97:4236-43. doi:10.1210/jc.2012-1836.

32. Catteau-Jonard S, Cortet-Rudelli C, Richard-Proust C, Dewailly D. Hyperandrogenism in Adolescent Girls. Endocr. Dev., vol. 22, 2012, p. 181-93. doi:10.1159/000326688.

33. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil. Steril. 2009; 91:456-88. doi:10.1016/j. fertnstert.2008.06.035.

34. Wiweko B, Maidarti M, Priangga MD, Shafira N, Fernando D, Sumapraja K, et al. Anti-mullerian hormone as a diagnostic and prognostic tool for PCOS patients. J. Assist. Reprod. Genet. 2014;31:1311-6. doi:10.1007/ s10815-014-0300-6.

35. Cimino I, CasoniF, Liu X, Messina A, Parkash J, Jamin SP, et al. Novel role for anti-Müllerian hormone in the regulation of GnRH neuron excitability and hormone secretion. Nat. Commun. 2016; 7: 10055. doi:10.1038/ ncomms10055.

36. Jayaprakasan K, Campbell BK, Hopkisson JF, Clewes JS, Johnson IR, Raine-Fenning NJ. Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone. Hum. Reprod. 2008;23:2577-83. doi:10.1093/humrep/den282.

37. Hong I-S, Klausen C, Cheung AP, Leung PCK. Gonadotropin-Releasing Hormone-I or -II Interacts with IGF-I/Akt But Not Connexin 43 in Human Granulosa Cell Apoptosis. J. Clin. Endocrinol. Metab. 2012; 97: 525-34. doi:10.1210/jc.2011-1229.

38. Nirgianakis K, Bersinger NA, McKinnon B, Kostov P, Imboden S, Mueller MD. Regression of the inflammatory microenvironment of the peritoneal cavity in women with endometriosis by GnRHa treatment. Eur. J. Obstet. Gynecol. Reprod. Biol. 2013; 170: 550-4. doi:10.1016/j.ejogrb.2013.08.010.

39. Muramatsu T. Structure and function of midkine as the basis of its pharmacological effects. Br.J. Pharmacol. 2014; 171: 814-26. doi:10.1111/bph.12353.

40. Osuga Y. Novel Therapeutic Strategies for Endometriosis: A Pathophysiological Perspective. Gynecol. Obstet. Invest. 2008; 66: 3-9. doi:10.1159/000148025.

41. Huang F, Wang H, Zou Y, Liu Q, Cao J, Yin T. Effect of GnRH-II on the ESC proliferation, apoptosis and VEGF secretion in patients with endometriosis in vitro. Int. J. Clin. Exp. Pathol. 2013; 6: 2487-96.

42. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res. Treat. 2009; 117: 561-7. doi:10.1007/ s10549-009-0313-5.

43. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage: prospective randomized study. Fertil. Steril. 2009; 91: 694-7. doi:10.1016/j.fertnstert.2007.12.044.

44. Blumenfeld Z, Avivi I, Eckman A, Epelbaum R, Rowe JM, Dann EJ. Gonadotropin-releasing hormone agonist decreases chemotherapy-induced gonadotoxicity and premature ovarian failure in young female patients with Hodgkin lymphoma. Fertil. Steril. 2008; 89: 166-73. doi:10.1016/j.fertnstert.2007.02.010.

45. Behringer K, Wildt L, Mueller H, Mattle V, Ganitis P, van den Hoonaard B, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2010; 21: 2052-60. doi:10.1093/annonc/mdq066.

46. Marder W, McCune WJ, Wang L, Wing JJ, Fisseha S, McConnell DS, et al. Adjunctive GnRH-a treatment attenuates depletion of ovarian reserve associated with cyclophosphamide therapy in premenopausal SLE patients. Gynecol. Endocrinol. 2012; 28: 624-7. doi:10.3109/09513590.2011.650752.

47. Clowse MEB, Behera MA, Anders CK, Copland S, Coffman CJ, Leppert PC, et al. Ovarian Preservation by GnRH Agonists during Chemotherapy: A Meta-Analysis. J. Women’s Heal. 2009; 18: 311-9. doi:10.1089/ jwh.2008.0857.

48. Shen Y-W, Zhang X-M, Lv M, Chen L, Qin T-J, Wang F, et al. Utility of gonadotropin-releasing hormone agonists for prevention of chemotherapy-induced ovarian damage in premenopausal women with breast cancer: a systematic review and meta-analysis. Onco Targets Ther. 2015; 8: 3349-59. doi:10.2147/OTT.S 95936.